Anti-schistosomal drugs: observations on the mechanism of drug resistance to hycanthone, and on the involvement of host antibodies in the mode of action of praziquantel.
This paper reports recent observations from our laboratory dealing with the anti-schistosome drugs hycanthone (HC) and praziquantel (PZQ). In particular, we discuss a laboratory model of drug resistance to HC in Schistosoma mansoni and show that drug sensitive and resistant lines of the parasite can be differentiated on the basis of restriction fragment length polymorphisms using homologous ribosomal gene probes. In addition, we summarize data demonstrating that effective chemotherapy of S. mansoni infection with PZQ in mice requires the presence of host anti-parasite antibodies. These antibodies bind to PZQ treated worms and may be involved in an antibody-dependent cellular cytotoxicity reactions which result in the clearance of worms from the vasculature.
Brindley
P J
PJ
Immunology and Cell Biology Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
Sher
A
A
D000818:Animals; D000909:Antibodies, Helminth / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity; D004351:Drug Resistance; D006826:Hycanthone / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D011223:Praziquantel / Q000494:pharmacology* / Q000627:therapeutic use; D012550:Schistosoma mansoni / Q000187:drug effects* / Q000276:immunology; D012555:Schistosomiasis mansoni / Q000188:drug therapy; D012556:Schistosomicides / Q000494:pharmacology* / Q000627:therapeutic use; D013892:Thioxanthenes / Q000494:pharmacology*
D000909:Antibodies, Helminth; D012556:Schistosomicides; D013892:Thioxanthenes; D006826:Hycanthone; D011223:Praziquantel